| |
| |
|
| Insider
Information: |
Hopkinson Craig C. |
| Relationship: |
Director |
| City: |
Waltham |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
120,204 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$3,170,972 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
120,204 |
|
|
| Total
Value |
$3,170,972 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alkermes Plc |
ALKS |
EVP R&D, Chief Medical... |
2024-02-23 |
109,709 |
2018-06-07 |
0 |
Premium* |
|
|
Albireo Pharma Inc |
ALBO |
Director |
2022-12-01 |
10,495 |
2022-12-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2024-02-23 |
4 |
D |
$29.57 |
$100,952 |
D/D |
(3,414) |
109,709 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2024-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,689 |
113,123 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2024-02-22 |
4 |
D |
$28.91 |
$157,617 |
D/D |
(5,452) |
105,434 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2024-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,278 |
110,886 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2024-02-20 |
4 |
D |
$30.39 |
$138,943 |
D/D |
(4,572) |
98,608 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2024-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,297 |
103,180 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2024-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,897 |
96,834 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2024-02-18 |
4 |
D |
$32.18 |
$127,143 |
D/D |
(3,951) |
92,883 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2024-02-08 |
4 |
D |
$26.77 |
$409,046 |
D/D |
(15,280) |
87,937 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2024-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
46,658 |
103,217 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2023-02-22 |
4 |
D |
$27.77 |
$148,431 |
D/D |
(5,345) |
56,559 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2023-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,038 |
61,904 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2023-02-21 |
4 |
D |
$27.77 |
$84,782 |
D/D |
(3,053) |
49,866 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2023-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,875 |
52,919 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2023-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,095 |
34,155 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2023-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
22,195 |
52,570 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2023-02-20 |
4 |
D |
$28.07 |
$289,289 |
D/D |
(10,306) |
46,044 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2023-02-18 |
4 |
D |
$28.07 |
$74,554 |
D/D |
(2,656) |
24,060 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,722 |
26,716 |
0 |
- |
|
| ALBO |
Albireo Pharma Inc |
Director |
– • – |
2022-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,495 |
10,495 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2022-02-23 |
4 |
AS |
$24.76 |
$296,650 |
D/D |
(11,983) |
17,994 |
0 |
% |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2022-02-22 |
4 |
D |
$25.01 |
$88,510 |
D/D |
(3,539) |
29,977 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2022-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,037 |
33,516 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2022-02-21 |
4 |
D |
$25.08 |
$50,712 |
D/D |
(2,022) |
21,479 |
0 |
- |
|
| ALKS |
Alkermes Plc |
EVP R&D, Chief Medical Officer |
• • – |
2022-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,875 |
23,501 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
